{"id":11570,"date":"2024-04-10T12:14:45","date_gmt":"2024-04-10T06:44:45","guid":{"rendered":"https:\/\/www.lalpathlabs.com\/blog\/?p=11570"},"modified":"2026-02-24T16:10:34","modified_gmt":"2026-02-24T10:40:34","slug":"apol-1-mediated-kidney-disease","status":"publish","type":"post","link":"https:\/\/www.lalpathlabs.com\/blog\/apol-1-mediated-kidney-disease\/","title":{"rendered":"APOL1-Mediated Kidney Disease"},"content":{"rendered":"

\"apol-1-mediated-kidney-disease\"<\/p>\n

APOL1-Mediated Kidney Disease\u00a0(AMKD) is a genetic condition, also known as APOL1-associated nephropathy. It is marked by a higher chance of kidney damage and chronic kidney disease<\/a> (CKD). Understanding this condition’s genetics and clinical implications is essential for early detection, risk assessment, and effective management.<\/p>\n

What is APOL1-Mediated Kidney Disease?<\/strong><\/h2>\n

APOL1 kidney disease\u00a0is caused by variants in the APOL1 (apolipoprotein L1) gene, which plays a role in the immune system’s defence against certain parasites.<\/p>\n

It is primarily associated with two common risk variants in the APOL1 gene: G1 and G2. People who inherit two copies of either G1 or G2 (homozygous) or one copy of each variant (compound heterozygous) are more likely to get kidney disease than those without them.<\/p>\n

The exact mechanisms between\u00a0APOL1 and kidney disease\u00a0are not fully understood. However, it is believed that they may lead to alterations in kidney function and structure, ultimately resulting in kidney damage and dysfunction.<\/p>\n

What are the Symptoms of APOL1-Mediated Kidney Disease?<\/strong><\/h2>\n

It’s important to note that symptoms can be different among individuals, and some people may not experience noticeable symptoms until the kidney disease has progressed significantly.<\/p>\n

Here are some\u00a0APOL1 kidney disease symptoms:<\/strong><\/p>\n

    \n
  1. Fatigue:\u00a0<\/strong>Reduced kidney function affects erythropoietin production, leading to anaemia<\/a> due to fewer red blood cells.<\/li>\n
  2. Swelling (Edema):<\/strong>\u00a0Kidney disease causes fluid imbalances, resulting in swelling in the ankles, legs, feet, or face.<\/li>\n
  3. Changes in Urine:<\/strong>\u00a0Foamy urine (excess protein), altered colour, clarity, and urine output (polyuria or oliguria) can occur.<\/li>\n
  4. High Blood Pressure:\u00a0<\/strong>Kidneys regulate blood pressure; controlling it is crucial in\u00a0APOL1 kidney disease.<\/li>\n
  5. Proteinuria:<\/strong>\u00a0Damaged kidney filters may allow proteins into the urine, indicating ongoing kidney damage.<\/li>\n
  6. Signs of Dysfunction:<\/strong>\u00a0Tests show elevated serum creatinine and reduced glomerular filtration rate (GFR) in kidney disease.<\/li>\n<\/ol>\n

    Note:<\/strong>\u00a0Serum creatinine is a waste substance that accumulates in the bloodstream when kidney functioning is impaired. Glomerular Filtration Rate (GFR) measures the kidney’s efficiency in filtering waste products from the blood.<\/p>\n

    What are the Causes of APOL1-Mediated Kidney Disease?<\/strong><\/h2>\n

    The primary cause is the generic inheritance of a risk variant in the APOL1 gene in kidney disease. Individuals who carry these variants are more susceptible to developing kidney disease, especially when exposed to additional risk factors like diabetes, hypertension, obesity, and certain medications.<\/p>\n

    While the prevalence of APOL1 risk variants is higher in individuals of African descent, it’s important to note that not everyone with these variants will develop kidney disease. Other environmental and genetic factors also affect the overall risk and progression of the condition.<\/p>\n

    What are the Tests used for APOL1-Mediated Kidney Disease?<\/strong><\/h2>\n

    Diagnosis of\u00a0APOL1-mediated kidney disease\u00a0involves several tests and evaluations. Some of these tests include:<\/p>\n

      \n
    1. Genetic Testing:<\/strong>\u00a0These tests can identify APOL1 risk variants (G1 and G2). This information helps assess the risk of developing kidney disease and can guide personalised management strategies.<\/li>\n
    2. Kidney Function Tests<\/a>:<\/strong>\u00a0Specific blood tests such as estimated Glomerular Filtration Rate (eGFR) and serum creatinine test can assess kidney function. Elevated creatinine levels and reduced eGFR indicate impaired kidney function.<\/li>\n
    3. Urine Analysis:<\/strong>\u00a0Urine tests, including urine protein-to-creatinine ratio (UPCR) and urine albumin-to-creatinine ratio (UACR), are performed to detect proteinuria and assess the severity of kidney damage.<\/li>\n
    4. Imaging Studies:\u00a0<\/strong>Kidney imaging, such as ultrasound or CT scan, may be recommended to evaluate kidney structure and detect abnormalities.<\/li>\n<\/ol>\n

      How to Manage APOL1-Mediated Kidney Disease?<\/strong><\/h2>\n

      The management of\u00a0APOL1-mediated kidney disease\u00a0aims to slow disease progression, reduce complications, and preserve kidney function. Key aspects of management include:<\/p>\n

        \n
      1. Blood Pressure Control:<\/strong>\u00a0Managing high blood pressure helps slow down kidney disease progression and lowers the chances of cardiovascular problems.<\/li>\n
      2. Proteinuria Management:<\/strong>\u00a0Strategies to reduce proteinuria may include dietary changes (reducing protein intake) and lifestyle modifications (weight management, regular exercise).<\/li>\n
      3. Monitoring Kidney Function:<\/strong>\u00a0Regular blood tests (creatinine, eGFR) and urine tests (proteinuria) track disease progression.<\/li>\n
      4. Lifestyle Modifications:<\/strong>\u00a0A balanced diet, regular exercise, smoking cessation, and limiting alcohol reduce complications.<\/li>\n
      5. Patient Education and Support:<\/strong>\u00a0Inform patients about their condition, treatment options, and lifestyle changes. Access to healthcare professionals and support groups enhances outcomes.<\/li>\n<\/ol>\n

        Individuals with APOL1-mediated kidney disease should consult their healthcare providers to tailor a personalised management plan. Regular monitoring is vital. Consider scheduling a protein creatinine test<\/strong><\/a> with Dr Lal PathLabs for a comprehensive assessment and tailored care.<\/p>\n

        FAQs<\/strong><\/h3>\n

        1. Is APOL1-mediated kidney disease common?<\/strong><\/h3>\n

        APOL1 risk variants are more prevalent in individuals of African descent, but the overall incidence of\u00a0APOL1 kidney disease varies among populations.<\/p>\n

        2. Can APOL1-mediated kidney disease be prevented?<\/strong><\/p>\n

        While the genetic risk cannot be altered, early detection, lifestyle changes (healthy diet, exercise), and medical management can help slow disease progression and reduce complications.<\/p>\n

        3. What are the chances of passing APOL1 risk variants to offspring?<\/strong><\/p>\n

        If both parents carry APOL1 risk variants, there is a chance of passing these variants to their children. Genetic counselling can provide information about inheritance patterns and risk assessment.<\/p>\n","protected":false},"excerpt":{"rendered":"

        APOL1-Mediated Kidney Disease\u00a0(AMKD) is a genetic condition, also known as APOL1-associated nephropathy. It is marked by a higher chance of kidney damage and chronic kidney disease (CKD). Understanding this condition’s genetics and clinical implications is essential for early detection, risk assessment, and effective management. What is APOL1-Mediated Kidney Disease? APOL1 kidney disease\u00a0is caused by variants […]<\/p>\n","protected":false},"author":6,"featured_media":11626,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1055,19],"tags":[1964],"acf":[],"_links":{"self":[{"href":"https:\/\/www.lalpathlabs.com\/blog\/wp-json\/wp\/v2\/posts\/11570"}],"collection":[{"href":"https:\/\/www.lalpathlabs.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lalpathlabs.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lalpathlabs.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lalpathlabs.com\/blog\/wp-json\/wp\/v2\/comments?post=11570"}],"version-history":[{"count":5,"href":"https:\/\/www.lalpathlabs.com\/blog\/wp-json\/wp\/v2\/posts\/11570\/revisions"}],"predecessor-version":[{"id":18476,"href":"https:\/\/www.lalpathlabs.com\/blog\/wp-json\/wp\/v2\/posts\/11570\/revisions\/18476"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.lalpathlabs.com\/blog\/wp-json\/wp\/v2\/media\/11626"}],"wp:attachment":[{"href":"https:\/\/www.lalpathlabs.com\/blog\/wp-json\/wp\/v2\/media?parent=11570"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lalpathlabs.com\/blog\/wp-json\/wp\/v2\/categories?post=11570"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lalpathlabs.com\/blog\/wp-json\/wp\/v2\/tags?post=11570"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}